2026 MIDD Webinar Series | Integrating Clinical Utility Index Modeling Approach for Antibody-Drug Conjugates

Includes a Live Web Event on 02/18/2026 at 12:00 PM (EST)

You must log in to register
- Member - Free!
Continue

Clinical Utility Indexes (CUIs) provide a quantitative, integrated measure of efficacy and safety within a scalable platform. Traditionally, benefit and risk are assessed through exposure-response (ER) analyses and compared qualitatively to choose a dose. CUIs transform this by combining multiple ER geometries into a single, reproducible, and flexible dose/PK exposure-dependent metric, often represented as a bell-shaped curve, with the peak CUI mapped to a nominal dose or regimen.

The MIDD Webinar Series, coordinated by Yash Kapoor and Fulya Akpinar Singh, is a series of webinars focused on shaping the future of drug development and regulatory decision-making sponsored by the ISoP Education Committee. Topics range from MIDD approaches in regulatory submission to pharmacometrics topics that are at the core of model development.

Venkatesh Pilla Reddy

Senior Director

Global PKPD and Pharmacometrics group at Eli Lilly and Company

Dr. Venkatesh Pilla Reddy is a Senior Director in the Global PKPD and Pharmacometrics group at Eli Lilly and Company in the UK. At Lilly, Venkatesh provides MIDD/PKPD Lead support for projects in oncology ADC and RLT projects and immunology. He earned his PhD in Pharmacometrics through a collaborative program involving Pfizer, Janssen Pharmaceuticals, and Merck via TI Pharma in the Netherlands. He was a Deputy Topic Leader at ICH, shaping the ICH M12 DDI guideline. He plays a leading role in influential cross-industry working groups, such as IQ TALG, ISOP, ASCPT, and ISSX M&S.